key: cord-0824777-ickqi7iw
authors: Lin, Chun-Yang; Wolf, Joshua; Brice, David C.; Sun, Yilun; Locke, Macauley; Cherry, Sean; Castellaw, Ashley H.; Wehenkel, Marie; Crawford, Jeremy Chase; Zarnitsyna, Veronika I.; Duque, Daniel; Allison, Kim J.; Allen, E. Kaitlynn; Brown, Scott A.; Mandarano, Alexandra H.; Estepp, Jeremie H.; Taylor, Charles; Molina-Paris, Carmen; Schultz-Cherry, Stacey; Tang, Li; Thomas, Paul G.; McGargill, Maureen A.
title: Pre-existing humoral immunity to human common cold coronaviruses negatively impacts the protective SARS-CoV-2 antibody response
date: 2021-12-07
journal: Cell Host Microbe
DOI: 10.1016/j.chom.2021.12.005
sha: e75dcb59ac71beddb5b3377d6877c722d5a7d19f
doc_id: 824777
cord_uid: ickqi7iw

SARS-CoV-2 infection causes diverse outcomes ranging from asymptomatic infection to respiratory distress and death. A major unresolved question is whether prior immunity to endemic, human common cold coronaviruses (hCCCoV) impacts susceptibility to SARS-CoV-2 infection or immunity following infection and vaccination. Therefore, we analyzed samples from the same individuals before and after SARS-CoV-2 infection or vaccination. We found hCCCoV antibody levels increase after SARS-CoV-2 exposure, demonstrating cross-reactivity. However, a case-control study indicates baseline hCCCoV antibody levels are not associated with protection against SARS-CoV-2 infection. Rather, higher magnitudes of pre-existing betacoronavirus antibodies correlate with more SARS-CoV-2 antibodies following infection, an indicator of greater disease severity. Additionally, immunization with hCCCoV spike proteins before SARS-CoV-2 immunization impedes generation of SARS-CoV-2 neutralizing antibodies in mice. Together, these data suggest pre-existing hCCCoV antibodies hinder SARS-CoV-2 antibody-based immunity following infection and provide insight on how pre-existing coronavirus immunity impacts SARS-CoV-2 infection, which is critical considering emerging variants.

The increase in hCCCoV antibodies following SARS-CoV-2 infection could be due to 215 activation of pre-existing memory B cells that were generated after prior hCCCoV 216 infection. Alternatively, the elevated levels of hCCCoV antibodies after SARS-CoV2 217 infection could be due to the generation of new antibodies in response to SARS-CoV-2 218 that cross-react to hCCCoV. To distinguish these possibilities, we measured antibody 219 levels in samples collected at various times after SARS-CoV-2 diagnosis. We reasoned 220 that an increase in hCCCoV antibodies due to a boost of pre-existing memory B cells 221 would be detected rapidly following diagnosis, while an increase in hCCCoV antibodies 222 resulting from newly generated antibodies would be evident later. Remarkably, the 223 levels of HKU1 IgG rapidly increased in several individuals within the first five days after 224 SARS-CoV-2 diagnosis ( Figure 3C, 3F) , and OC43 and HKU1 IgA increased within 10 225 days in over 50% of individuals (Figure 3E, 3H) . The early rise in betacoronavirus 226 hCCCoV IgG and IgA antibodies suggests that infection with SARS-CoV-2 activates 227 pre-existing memory B cells to boost antibodies generated during prior hCCCoV 228

infections. Further, if the increase in hCCCoV antibodies was due to newly generated 229 antibodies in response to SARS-CoV-2 infection, then we would expect these 230 antibodies to also be SARS-CoV-2-specific. Therefore, we examined whether 231 individuals with high levels of HKU1 IgG antibodies within five days of diagnosis also 232 had antibodies that recognized SARS-CoV-2 spike or RBD. While a few individuals had do not bind SARS-CoV-2 with sufficient avidity to be detected by ELISA.

Since hCCCoV-specific antibodies cross-react with SARS-CoV-2 as demonstrated by 255 the early increase after infection and prior studies (Ladner et al., 2020; Ng et al., 2020), 256

we performed a large, case-control study to test whether pre-existing hCCCoV IgG, 257

IgM, and IgA antibodies were different between individuals who became infected during 258

the study compared to individuals that remained negative. It is important to note that all 259 individuals underwent weekly nasal swab screening, which allowed us to identify 260 asymptomatic infections and confirm all SARS-CoV-2 infections by PCR. We assessed 261 baseline hCCCoV antibodies in 121 individuals that subsequently became positive 262 during the study and compared them to baseline samples of 1081 individuals that 263 remained uninfected. Even though hCCCoV antibodies exhibit sufficient cross-reactivity 264 with SARS-CoV-2 to increase after infection, baseline levels of hCCCoV antibodies 265

were not different between individuals that became infected compared to those that 266 remained SARS-CoV-2 negative during the study period (Figure 4 and Supplemental 267 Table 3 ). These data imply that prior infection with hCCCoV does not protect against 268 infection with SARS-CoV-2, which is consistent with the inability of hCCCoV-specific 269 antibodies to neutralize SARS-CoV-2 (Aguilar-Bretones et al., 2021; Legros et al., 2021; 270 Poston et al., 2020) . 271

While baseline levels of hCCCoV antibodies were not different between participants that 274 became infected compared to those who remained SARS-CoV-2 negative, hCCCoV 275 antibodies could influence the severity or duration of symptoms. Therefore, we 276 assessed whether there was a correlation with disease severity and baseline levels of 277 hCCCoV antibodies. Infected individuals were given a score of 1-5 based on an a priori 278 ordinal scale as follows: (1) asymptomatic, (2) mild-moderate, (3) moderate-severe 279 illness, (4) severe illness, (5) critical illness. This scale allowed us to distinguish truly 280 asymptomatic, minimally symptomatic, and more severely symptomatic individuals. 281

Most participants in this cohort had mild-moderate and moderate-severe (severity 282 scores 2-3) severity scores. Since only a few individuals were asymptomatic, severe, or 283 critical, we compared baseline hCCCoV antibodies between individuals that were either 284 asymptomatic or had mild disease (severity score of 1-2) to individuals that experienced 285 moderate, severe, or critical disease (severity score 3-5). We found no significant 286 difference between baseline hCCCoV antibody levels and disease severity when 287 comparing these two groups ( Figure 5A and 5B) . Moreover, symptom duration did not 288 correlate with baseline hCCCoV antibody levels ( Figure 5A and S5). These data 289

suggest that the baseline levels of hCCCoV antibodies do not provide significant 290 protection against SARS-CoV-2 infection. However, as there were few cases of severe 291 COVID-19 requiring hospitalization or critical illness in the included participants, our 292 ability to identify predictors of these states is limited. 293

Since the SJTRC cohort consists primarily of individuals with mild-moderate disease 295 severity and only four individuals had severe or critical disease, the impact of hCCCoV 296 antibodies on very severe cases may not be evident in this cohort. Many studies 297

reported that the level of SARS-CoV-2 spike or RBD IgG or IgA following infection 298 individuals with more severe disease likely have more viral replication and therefore, 302 greater antigen exposure. Thus, the antibody response after infection may provide a 303 means to further stratify disease severity within the groups, independent of self-reported 304 J o u r n a l P r e -p r o o f symptoms. Therefore, we examined whether the antibody response 16-40 days 305

following SARS-CoV-2 infection correlated with disease severity in the SJTRC cohort, in 306 which most participants had mild-moderate disease severity. Importantly, none of the 307 infected individuals had received a vaccine prior to collection of samples used for this 308 comparison or other comparisons reported here. Similar to other studies, the level of 309

IgG specific for SARS-CoV-2 spike, RBD, and N protein significantly correlated with 310 increased disease severity scores ( Figure 6A and S6) . Higher spike and RBD IgM and 311 spike IgA levels also correlated with more severe disease. These data indicate that 312 although most participants had mild-moderate disease, the levels of SARS-CoV-2-313 specific IgG and IgM correlated with severity. Consequently, we compared baseline 314 hCCCoV antibody levels to SARS-CoV-2 antibody levels following infection to further 315 assess association of baseline hCCCoV and a distinct correlate of disease severity. 316

Interestingly, higher levels of OC43 IgG prior to infection correlated with increased 317 SARS-CoV-2 IgG after infection (Figure 6B) , raising the possibility that high baseline 318 OC43 IgG may be associated with more severe disease. 319

To further examine the impact of hCCCoV immunity on the immune response to SARS-320

CoV-2, we tested whether the magnitude of the hCCCoV antibody increase or decrease 321 following SARS-CoV-2 infection impacted SARS-CoV-2 antibody levels. The amount 322 that the hCCCoV antibody levels increase in the initial days after SARS-CoV-2 infection 323 is indicative of the extent that memory B cells are activated to produce antibody. Thus, 324

we calculated percent change of hCCCoV antibody in the baseline sample to the 325 sample taken within the first 15 days after diagnosis. Increases in hCCCoV antibody 326 levels in this time frame would reflect the extent of memory B cell activation. We 327 compared this change to the SARS-CoV-2 antibody levels 16-40 days after infection, as 328 these levels correlated with disease severity in our cohort as well as several other 329 studies. Interestingly, a greater increase in betacoronavirus IgG and IgA was associated with higher levels of SARS-CoV-2 IgG and IgM antibodies after infection ( Figure 6C) . 331

Since increased levels of SARS-CoV-2 IgG and IgM are associated with greater 332 disease severity, these data raise the possibility that the early increase (1-15 days after 333 infection) in hCCCoV antibodies could be associated with higher disease severity. 334

Alternatively, the association between the increase in hCCCoV antibody levels with 335 higher SARS-CoV-2-induced antibodies could be due to newly generated antibodies in 336 response to SARS-CoV-2 infection that cross-react with hCCCoVs. However, analysis IgA and IgG correlate with a higher antibody response to SARS-CoV-2 following 372 infection, but not vaccination. As increased SARS-CoV-2 antibodies after infection 373 correlated with greater disease, these findings raise the possibility that pre-existing 374 betacoronavirus IgG and IgA negatively impact the immune response to SARS-CoV-2, 375 which results in greater duration of antigen and therefore more SARS-CoV-2 antibodies. 376

Since most individuals have positive levels of antibodies specific for all four hCCCoV 379 ( Fig. 1D) , it is not possible to directly examine whether prior exposure to a particular 380 hCCCoV impacts the antibody response to SARS-CoV-2. Therefore, we performed a 381 series of immunizations in mice that had no prior exposure to coronaviruses. C57BL/6 mice were immunized with the spike proteins of SARS-CoV-2, OC43, HKU1, 229E, or 383 NL63. Four weeks later, all mice were immunized with the SARS-CoV-2 spike protein. 384

Two weeks following immunization with SARS-CoV-2 spike, we measured RBD and 385

spike IgG antibodies to determine if prior exposure to hCCCoV spike proteins impacted 386 the antibody response to SARS-CoV-2 spike and RBD. Prior immunization with 387 hCCCoV spike proteins did not significantly impact antibody levels to SARS-CoV-2 full-388 length spike ( Figure 7A ). However, RBD IgG was significantly decreased in mice that 389 received a prior immunization with HKU1 and NL63 spike proteins compared to mice 390 only immunized with SARS-CoV-2 spike protein ( Figure 7B ). Importantly, prior 391 immunization with any of the hCCCoV spike proteins inhibited neutralizing antibodies 392

following SARS-CoV-2 spike immunization as detected by a pseudo-neutralization 393 assay ( Figure 7C ). These data, which are consistent with a prior study utilizing a 394 different strain of mice and adjuvant (Lapp et al., 2021) , directly demonstrate that prior 395 exposure to hCCCoV spike proteins has the potential to inhibit generation of 396 neutralizing antibodies specific for the RBD of SARS-CoV-2. Together, these findings 397 illustrate that prior immunity to a virus with a certain degree of homology can impede the 398 immune response to a novel virus. 399

Immune imprinting refers to preferential activation of memory B cells that were 401 primarily Caucasian females with mild to moderate symptoms. Therefore, we were not 432 able to thoroughly assess associations with more severe disease. Regardless, our data 433 suggest that hCCCoV immunity may be an additional factor that can impede effective immunity to SARS-CoV-2 infection. Considering the continued circulation of SARS-CoV-435 2 variants, it will be important to further investigate mechanisms in which pre-existing 436 immunity impacts the immune response to a novel, but related virus. 437

Prior studies investigating whether hCCCoV antibodies contributed to disease severity 438 yielded particularly contradictory results. One main reason for these divergent 439 conclusions is that most of the previous studies lacked baseline samples from the same not be a reliable indicator of the hCCCoV to which an individual was most recently 454 exposed. This is evident in the greater correlation between antibody isotypes specific for 455 different hCCCoVs rather than an association with high levels of IgA, IgM, and IgG 456 specific for a particular hCCCoV. Consistent with previous studies, we found that in 457 older individuals, hCCCoV immunity is more biased toward IgA and IgG, rather than IgM 458 compared to younger individuals (Selva et al., 2021) . Each time an individual is exposed 459 to a hCCCoV, the memory B cells are further fine-tuned through affinity maturation and clonal selection to generate higher affinity hCCCoV-specific antibodies. Accordingly, as 461 individuals age, repeated exposure to hCCCoV creates a more specific and less 462 adaptable repertoire of hCCCoV-specific memory B cells. Since SARS-CoV-2 is a novel 463 virus that individuals had not encountered, it was unexpected that IgM antibodies did 464 not precede IgG antibodies ( Figure S3) . These data are consistent with a previous 465 report and suggest that the early immune response to SARS-CoV-2 is dominated by imply a more narrow and less adaptable antibody repertoire, which would be 471 advantageous for immunity to the hCCCoV, but detrimental to the immune response to 472 a novel coronavirus. Thus, although younger individuals may be exposed to hCCCoV 473 more often than older individuals, the hCCCoV IgM bias in younger participants is 474 consistent with a more adaptable repertoire, which may explain why younger individuals 475 exhibit less disease severity than older individuals. 476

Although baseline hCCCoV antibody levels correlated with SARS-CoV-2 antibody levels 477

following infection, we did not observe an association between baseline hCCCoV 478 immunity and SARS-CoV-2 antibodies after vaccination. Many factors differ between the 479 immune response to vaccination compared to infection. One possibility is that pre-existing 480 hCCCoV antibodies may impede the generation of SARS-CoV-2 neutralizing antibodies, 481 thereby extending viral exposure, and enhancing the antibody response after infection. 482

However, inhibition of neutralizing antibodies would not impact antigen load in the context 483 of a vaccination, and therefore hCCCoV immunity would not have a similar impact on 484 infection and vaccination. Alternatively, it is also possible that there is no correlation 485 between baseline hCCCoV antibody levels and antibody levels following vaccination because the mRNA vaccines induce such a robust immune response to the SARS-CoV-487 2 spike protein that the efficacy of these vaccines may override the effect of imprinting. 488

Interestingly, a recent report showed that imprinting also led to divergent outcomes 489 following influenza virus infection versus vaccination (Dugan et al., 2020) . 

Limitations of our study include the low number of participants that experienced severe 500 disease. Thus, we performed comparisons of baseline hCCCoV antibody levels to 501 disease severity by grouping individuals with severity scores of 1-2 versus 3-5, which may 502 not have revealed factors that specifically correlate with greater disease severity. 503

Moreover, as our cohort consisted of employees, it did not include any individuals below 504 18 years of age and not many older than 65 years of age. 505

We thank the donors who volunteered for the SJTRC study, Florian Krammer for suppling 507 critical reagents, Rachael Keating for critical reading of the manuscript, Benjamin A. Health Science Center/Le Bonheur Children's Hospital approved the study. Written, 655

informed consent was acquired from participants' parents or guardians and written 656 assent from age-appropriate subjects was acquired at the time of enrollment. Index 657 cases provided nasal swabs, nasal lavages, and blood on the day of enrollment (day 0) 658 and days 3, 7, 10, and 28, whereas household contacts provided nasal swabs on days 659 0, 3, 7, and 14 and blood and nasal lavages on days 0 and 28. The population used for 660 these analyses was predominantly African American (81.4%) with 18.6% Caucasian 661 participants (n = 86). Metadata collected from this study included information on several 662 symptoms that were ranked daily (self-reported) according to a visual analog scale. 663

Samples included in the analysis of supplemental Figure 2 included individuals that 664

were negative for influenza infection upon enrollment and became infected during the 665 study. 666

Expi293F cells were cultured in suspension using PETG Erlenmeyer flasks within a 668 37°C incubator with ≥80% relative humidity and 8% CO2 on an orbital shaker platform 669 rotating at 135rpm. They were cultured in Expi293™ Expression Medium (Thermo 670 Fisher Scientific; A1435101) according to the manufacturer's instructions until 671 transfection (described below). These cells were derived from the HEK 293 human 672 embryonic kidney cell line, which was karyotyped as female. Cells were purchased from 673 a commercial vendor and not further authenticated. 674

Participants who were diagnosed with SARS-CoV-2 during the study provided 677 information four weeks after diagnosis about the symptoms and interventions they had 678 during the period of infection. Severity was classified on an a priori ordinal scale based 679 on data provided by the participants as: 1. Asymptomatic (no attributable symptoms); 2. Mild-moderate (any attributable symptoms, other than shortness of breath, that did not 681 require hospitalization or supplemental oxygen); 3. Moderate-severe illness with 682

shortness of breath not requiring hospitalization or supplemental oxygen; 4. Severe 683 illness requiring hospitalization or supplemental oxygen for ≥1 hour; and 5. Critical illness (requiring admission to ICU, vasopressors or hemodialysis). Weekly surveillance 685 by nasal swab and PCR enabled us to identify asymptomatic infections. Therefore, this 686 scale was chosen to distinguish truly asymptomatic, minimally symptomatic, and more 687 severely symptomatic individuals. 688

Expression plasmids for the nucleocapsid (N) protein, spike protein, and the spike 690 to optimize sensitivity and specificity. SARS-CoV-2 spike RBD was coated at 2 µg/ml in 702 PBS for each isotype detection. Full-length spike was coated at 2 µg/ml for IgG and 4 703 µg/ml for either IgM or IgA detection. N protein was coated at 1 µg/ml for IgG detection 704 (1:2,000; Southern Biotech, 2050-05). The plates were washed and incubated at room 716 temperature with OPD (Sigma-Aldrich; P8287) for ten minutes (for hCCCoV ELISAs) or 717 SIGMAFAST OPD (Sigma-Aldrich; P9187) for eight minutes (for SARS-CoV-2 ELISAs). 718

The chemiluminescence reaction was stopped by addition of 3N HCl and absorbances 719

were measured at 490 nm on a microplate reader. To ensure the specificity of this 720 assay, we first screened samples from a prior study that included young children to 721 identify samples to serve as negative controls. In addition, as a control for plate-to-plate 722 variability, we selected two positive samples from the SJTRC cohort that were tested on 723 each plate and used to calculate the percent ratio, which is the OD of each sample 

CoV-2 surrogate neutralization assay. P-values calculated using Kruskal-Wallis test

Dunn's multiple comparisons test (*, p < 0.05; **

Seasonal coronavirus-specific B cells with limited SARS-CoV-2 cross-reactivity 785 dominate the IgG response in severe COVID-19

SNP-mediated 788 disruption of CTCF binding at the IFITM3 promoter is associated with risk of severe 789 influenza in humans

A serological 792 assay to detect SARS-CoV-2 seroconversion in humans

Seasonal 795 human coronavirus antibodies are boosted upon SARS-CoV-2 infection but not 796 associated with protection

Lack of 831 antibodies against seasonal coronavirus OC43 nucleocapsid protein identifies patients 832 at risk of critical COVID-19

Compact Hash Digests of R Objects

Seasonal coronavirus 838 protective immunity is short-lasting

Epidemiological, comorbidity factors with severity and prognosis of

COVID-19: a systematic review and meta-analysis

Antibody landscapes after influenza 844 virus infection or vaccination

Molecular Evolution of Human 846

An R Companion to Applied Regression Gombar

SARS-CoV-2 infection and COVID-19

severity in individuals with prior seasonal coronavirus infection

Health care 858 worker sero-monitoring reveals complex relationships between common coronavirus 859 antibodies and COVID-19 symptom duration

circlize implements and 861 enhances circular visualization in R

Complex heatmaps reveal patterns and 863 correlations in multidimensional genomic data

Cross-reactive antibody against human coronavirus OC43 spike 866 protein correlates with disease severity in COVID-19 patients: a retrospective study

Harnessing immune history to combat 869 influenza viruses

Analysis of 877

Humoral Immune Responses in Patients With Severe Acute Respiratory Syndrome 878

Coronavirus 2 Infection

Serologic Cross-881 Reactivity of SARS-CoV-2 with Endemic and Seasonal Betacoronaviruses

TestCor: FWER and FDR Controlling Procedures for Multiple 884

Correlation Tests

The potential danger of suboptimal antibody 886 responses in COVID-19

rstatix: Pipe-Friendly Framework for Basic Statistical Tests

Package 'factoextra'. Extract and visualize the 889 results of multivariate data analyses

Human Coronavirus NL63

Molecular Epidemiology and Evolutionary Patterns in Rural Coastal Kenya

Original antigenic sin responses 900 to Betacoronavirus spike proteins are observed in a mouse model, but are not apparent 901 in children following SARS-CoV-2 infection

A longitudinal study of SARS-CoV-2-infected 904 patients reveals a high correlation between neutralizing antibodies

Molecular signatures 908 of antibody responses derived from a systems biology study of five human vaccines

Evolution of Early SARS-CoV-2 and 912

)), ctb] (port to

Finding Groups in Data

S Protein-Reactive IgG and Memory B

Cell Production after Human SARS-CoV-2 Infection Includes Broad Reactivity to the S2

vegan: Community Ecology

Seven-month kinetics of SARS

CoV-2 antibodies and role of pre-existing antibodies to human coronaviruses

Mucosal immune 935 responses predict clinical outcomes during influenza infection independently of age and 936 viral load

Absence of SARS-CoV-2 neutralizing activity in pre-pandemic sera 939 from individuals with recent seasonal coronavirus infection

Cross-Sectional

Evaluation of Humoral Responses against SARS-CoV-2 Spike

psych: Procedures for Psychological, Psychometric, and Personality 946 Research

Cross-Reactive Immune Responses toward the

Common Cold Human Coronaviruses and Severe Acute Respiratory Syndrome 952

Coronavirus 2 (SARS-CoV-2): Mini-Review and a Murine Study

Systems 956 serology detects functionally distinct coronavirus antibody features in children and 957 elderly

Viral epitope profiling of COVID-19 patients 960 reveals cross-reactivity and correlates of severity

Package 'survival

seaborn: statistical data visualization

Severe COVID-19 patients display a back boost of seasonal 972 coronavirus-specific antibodies